Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Lenvatinib + Letrozole
DRUG
2 trials
Sponsors
National University Hospital, Singapore
Conditions
Breast Cancer
Phase 1
Neoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer
Active, not recruiting
NCT02562118
National University Hospital, Singapore
Breast Cancer
Start: 2015-10-02
End: 2027-06-30
Target: 40
Updated: 2025-09-25
Phase 2
Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor
Recruiting
NCT05181033
National University Hospital, Singapore
Breast Cancer
Start: 2021-12-27
End: 2027-08-31
Target: 120
Updated: 2025-07-25
Related Papers
Clinical efficacy and molecular effects of lenvatinib (Len) and letrozole (Let) in hormone receptor-positive (HR+) metastatic breast cancer (MBC).
Journal of Clinical Oncology
2020-05-20
1 citations
A phase Ib/II trial of lenvatinib (len) and letrozole (let) incorporating pharmacodynamics studies in postmenopausal women with hormone receptor positive (HR+) locally advanced/metastatic breast cancer (LABC/MBC).
Journal of Clinical Oncology
2019-05-20
3 citations